根据Exact Sciences的建模数据预测，在过去10年中，已有超过1600万人通过Cologuard测试完成了筛查。这也推动了美国50-75岁群体的结肠癌筛查率，从2015年的63%上升到2021年的72%。 这一极具社会价值的成就，为Exact ...

In a separate study published in March by the same journal, an updated version of the Cologuard stool test, which also looks ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

In July, the Summer Law and Trial Institute (SLTI) welcomed 24 high school students from across the state of Ohio both to Athens and to the practice of law. OHIO's faculty and staff, across various ...

Imagine watching your dog waddle into the room and noticing that he is walking on the top of his back paw. While you may ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

A team from Kumamoto University has uncovered a new mechanism that could revolutionize infertility care by promoting embryo ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...